MedTrace Logo

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

NCT00368277 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 901

Last updated 2011-03-25

Study results available
· View outcomes & findings →

Summary

Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.

Conditions

Interventions

DRUG

Aliskiren

Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning

DRUG

Ramipril

Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning

DRUG

Hydrochlorothiazide

Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning

DRUG

Amlodipine

Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00368277 on ClinicalTrials.gov